On this day eight years ago I made my first post on fatherdad.com. That was the first ever post by a black "daddy blogger." I searched high and low for one before I determined that I was it. I think that post is a hilariously bad and somewhat profound (and very much unnoticed) internet milestone. [...]
It comes without any great surprise, but earlier in the month the FDA announced they were giving the application from Astellas and Medivation for a priority review to extend the indication (FDA approved use) for Xtandi (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. The [...]
It is a widely understood that androgen deprivation therapy (ADT) causes adverse side effects and events. Some researchers believe that the ADT-induced alterations in lipid and glucose metabolism may be race-dependent. To evaluate this concern the researchers recruited Japanese men with newly diagnosed prostate cancer who also underwent at least one year of ADT. They [...]
Please complete this ten minute, four question, anonymous survey about your thoughts around prostate cancer support and advocacy. Click>>> https://www.surveymonkey.com/s/CCRNTQP Your answers will help us to plan future prostate cancer support and advocacy actions on your behalf. Please feel encouraged to contact me by email at joel@malecare.org with any questions or concerns about this brief survey.
Current Prognostic models for overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) have become dated. They don’t adequately reflect the many new drugs used in clinical practice. To develop a relevant model data from a phase III trial of 1,050 men with mCRPC were used (Cancer and Leukemia Group B CALGB-90401 [Alliance]) was evaluated. [...]